Trial Profile
Natalizumab (Tysabri) High Resolution MRI and Clinical Immunology-Correlative Observational Study in Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jun 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms THRIFT-MS
- Sponsors Biogen
- 23 Dec 2014 Accrual to Date is 100 % according to the United Kingdom Clinical Research Network record.
- 23 Dec 2014 Planned number of patients changed from 18 to 40 as reported by United Kingdom Clinical Research Network record.
- 23 Dec 2014 Planned End Date changed from 31 Jan 2015 to 16 Oct 2014 as reported by United Kingdom Clinical Research Network record